New Season and Our Resilience to Tackle COVID
Below is my monthly message for the October 2021 edition of the MHRI newsletter, Focus. You can view Focus online at MedStarResearch.org/FOCUS.
Dear Friends and Colleagues,
Welcome to October 2021 filled with a week of beautiful, crisp fall weather but
also filled with ongoing pandemic concerns. What seems to be compounding
the situation is the lack of reliable information around so many aspects of
this disease. It would be nice to have clear answers to some of our most
critical questions such as:
- Does mask wearing really make a
difference if I am already vaccinated?
- When do I develop antibodies
from the vaccine and how long do they last?
- If I get COVID, how do I know
if I am going to get very sick or at high risk to die?
- If I go to an emergency room
with COVID, how do I know if it is safe to go home?
- Once I recovered from COVID,
how long do I have antibodies against further disease?
- How long will COVID symptoms
persist after the infection is over?
- Why can’t someone come up with
a simple pill to treat this disease?
Results
from MedStar Health’s
Centers for Disease Control and Prevention (CDC) Community Research Partnership
(CRP) Study of COVID-19 – This population health study, led by Drs Weintraub
and Miller, enrolled over 10,000 MedStar Health patients and is answering many
of the above questions about how our behaviors (mask wearing, social distancing,
etc) and vaccination uptake are having dramatic effects in our community.
Be on the lookout for an upcoming New England Journal of Medicine publication
(and over 20 other scientific publications) coming out from this study in the
next few months!
MedStar
Health Receives FDA Clearance to Trial an Oral Immunomodulatory Drug for
COVID-19 -
Drs. Fishbein, Khan, Kroemer and others from MedStar Georgetown Transplant
Institute last week received FDA clearance to conduct an investigator initiated
clinical trial on a novel oral medication to treat COVID-19.
MedStar
Health Investigators Evaluate Trends For Substance Use during the COVID-19
Pandemic -
This multi-disciplinary research team examined over 100,000 substance use
screens from across 7 MedStar Health emergency departments and recently
published their results ‘Impact of COVID-19 pandemic on emergency
department substance use screens and overdose presentations’ in The American
Journal of Emergency Medicine.
A New
AHRQ R21 Award will Study When is it Safe to Discharge a COVID-19 Patient from
the Emergency Department - In her first federally funded award, Dr.
Galarraga (an emergency medicine physician and health care delivery researcher)
will develop an electronic health record screening tool that uses artificial
Intelligence/machine learning to predict the risk of Emergency Department
return among COVID-19 patients.
The pandemic may be relentless but so are our MedStar Health
investigators! As of a recent review, we have over 250 COVID-related
research projects at MedStar Health across a diverse set of clinical
disciplines. We are advancing health across our community at the time of
greatest need. Thank you to all the research teams working on COVID-19
(and the other very important areas of healthcare!) and thank you to all those
who support the research teams to make this important work possible.
Enjoy this month’s issue of FOCUS and stay well.
Neil
Read Focus online at MedStarResearch.org/FOCUS.
Comments
Post a Comment